Research

New study supports remdesivir as COVID-19 treatment

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Recurrent UTIs linked to hidden reservoir

Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.

Jeff Balser, MD, PhD, left, Jennifer Pietenpol, PhD, and Eric Skaar, PhD, pose for a photo during a recent tour of new space for the Vanderbilt Institute for Infection, Immunology and Inflammation.

New space bolsters infectious disease and immunology discovery

The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) recently moved into its new research and administrative home.

Keeping beta cells “fit”

Vanderbilt cell biologists are defining the factors that help beta cells in the pancreas stay healthy, secrete insulin and prevent diabetes initiation and progression.

Kripalani to lead Center for Health Services Research

Sunil Kripalani, MD, MSc, professor of Medicine at Vanderbilt University Medical Center, has been appointed director of the Vanderbilt Center for Health Services Research.

lungs

New clues to lung-scarring disease may aid treatment

Scientists at Vanderbilt University Medical Center and the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have discovered previously unreported genetic and cellular changes that occur in the lungs of people with pulmonary fibrosis (PF).

1 65 66 67 68 69 125